What would it take to end endometriosis?
For decades, endometriosis has largely been approached through pain management, hormonal suppression and surgery. These approaches can be essential — but they do not answer the central scientific question.
Can the pathological programme that allows an endometriotic lesion to survive, invade and return be interrupted at its molecular source?
NBetaX™ was created around that question. Its ambition is not another temporary reduction in symptoms. Its ambition is a short-course, non-hormonal precision treatment capable of driving lesion regression, extinguishing the inflammatory environment that sustains disease, preserving healthy reproductive biology and reducing the likelihood of recurrence.
This is the cure question. NBetaX™ exists to pursue it.
The nuclear threshold.
β-catenin performs several legitimate functions within healthy tissue. At the cell membrane, it contributes to cell–cell adhesion through cadherin-associated complexes. Its behaviour changes when pathological signalling causes β-catenin to accumulate in the cytoplasm and enter the nucleus.
Inside the nucleus, β-catenin can participate in transcriptional programmes associated with:
- ProliferationCell division and lesion growth
- InvasionMigration into surrounding tissue
- EMTEpithelial–mesenchymal transition
- AngiogenesisNew blood-vessel signalling
- MatrixExtracellular-matrix production
- FibrosisScarring and adhesion biology
- PersistenceLesion survival and recurrence
Do not indiscriminately eliminate β-catenin. Intervene at the pathological nuclear event.
NBetaX™ investigates peptides engineered to restrict disease-associated β-catenin nuclear activity while preserving essential physiological functions elsewhere in the cell.
The thesis in the primary literature. The Wnt/β-catenin pathway was proposed as a therapeutic target in endometriosis in 2014, and the evidence since spans reviews, human-cell studies and animal models:
- Targeting the Wnt/β-catenin pathway in endometriosis: a potentially effective approach for treatment and prevention — Matsuzaki S et al., Molecular and Cellular Therapies, 2014 (review)
- Targeting the Wnt signaling network in endometriosis: mechanistic insights and translational opportunities† — Ye X et al., Biology of Reproduction, 2026 (review)
- β-catenin signaling inhibitors ICG-001 and C-82 improve fibrosis in preclinical models of endometriosis — Hirakawa T et al., Scientific Reports, 2019 (in vitro and animal)
NBetaX is both a name and a mechanistic objective.
One peptide. Four required capabilities.
For an NBetaX™ candidate to succeed, it must be designed to achieve four connected objectives. This is not conventional symptom suppression — it is precision control of a pathological intracellular state.
Reach the tissue
Reach or become preferentially active within pathological endometriosis tissue.
Cross the barrier
Cross the cellular barrier and access the intracellular compartment in which β-catenin signalling is operating.
Bind the interface
Bind a selected molecular interface involved in β-catenin trafficking or transcriptional activity.
Permit regression
Interrupt lesion-supporting signalling strongly enough to permit regression, immune clearance and durable remission.
The modality in the primary literature. Peptides and peptidomimetics that bind β-catenin protein-protein interfaces directly — the class of molecule capabilities 02–04 require — have been published since 2017, in chemical-biology and oncology contexts rather than in endometriosis:
- Cell Permeable Stapled Peptide Inhibitor of Wnt Signaling that Targets β-Catenin Protein-Protein Interactions — Dietrich L et al., Cell Chemical Biology, 2017
- Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors — Sang P et al., PNAS, 2019
- Inhibition of Wnt Signaling Using Axin Peptidomimetics through Direct Targeting of β-Catenin — Sang P et al., Journal of Medicinal Chemistry, 2026
N-BX01™
The first endometriosis-focused NBetaX candidate — a novel, independently engineered peptide, synthesized by Bogdan Dicoias on the SYNTHESERACT™ CF-SPPS machine, intended to investigate selective interference with pathological β-catenin nuclear signalling in endometriosis-associated cells.
- TargetIntracellular target engagement
- MechanismNon-hormonal nuclear β-catenin exclusion
- ActivityLesion-directed biological activity
- PreservePreservation of ovarian cyclicity
- ReduceLesion-associated inflammation
- ReduceInvasion and fibrotic remodelling
- SchedulePotential for short-course administration
- DurabilityPotential for durable remission after treatment ends
NBetaX → N-BX → N-BX01
NBetaX™ is the platform, the biological thesis and the wider therapeutic class. N-BX™ is the translational identity and candidate family. N-BX01™ is the lead nuclear β-catenin exclusion peptide for endometriosis.
Enter the N-BX01 programmeThe research began with a different question.
Bogdan Dicoias did not begin by asking how another endometriosis medicine could be produced. He began by asking why a disease affecting the lives, fertility and autonomy of millions remains something patients are expected to suppress indefinitely.
His work across the Panacea Bio Chem research universe has centred on peptide engineering, synthesis technology, formulation behaviour, preservation, controlled delivery and the machinery required to transform molecular concepts into physical candidates.
NBetaX™ brings those disciplines together around one objective: to design a peptide capable of stopping endometriosis at an intracellular control point rather than temporarily silencing the body around it. The programme is founder-directed, mechanism-led and built to progress from molecular design through synthesis, analytical characterisation, biological testing and clinical translation.
A programme designed backwards from the patient.
NBetaX™ is structured around the requirements of eventual clinical translation. Each stage illuminates as a real milestone is reached; the stages ahead remain outlined.
From interface to candidate
Identification of β-catenin-associated molecular interfaces relevant to pathological nuclear activity, then design of peptide variants for affinity, selectivity, stability, cellular entry and lesion-directed activity.
Idea to physical peptide
The N-BX candidate series is synthesized by Bogdan Dicoias on SYNTHESERACT™ — his own CF-SPPS continuous-flow solid-phase peptide synthesis platform — then characterised for identity, mass, purity, impurity mapping, aggregation, solubility and stability.
Mechanism to efficacy
Cell entry, intracellular localisation, target engagement, β-catenin redistribution and downstream transcription — then lesion regression, inflammation, fibrosis, reproductive-cycle preservation and recurrence after withdrawal.
“Cure” must become a measurable scientific standard.
Within the NBetaX™ programme, a potential cure would not simply mean that pain improved during treatment. It would require a far higher standard. The ambition is not to use the word lightly — the ambition is to make the word measurable.
- ◆No detectable active lesions by standardised assessment
- ◆Resolution of lesion-associated inflammatory activity
- ◆No requirement for continuing hormonal suppression
- ◆Preservation of physiological ovarian function
- ◆Sustained symptom remission after treatment withdrawal
- ◆No clinically meaningful recurrence over prolonged follow-up
Separating treatment from suppression.
No permanent hormonal suppression
A disease-directed treatment could separate endometriosis therapy from chronic endocrine suppression.
No repeated surgical cycle
Successful lesion resolution could reduce dependence on repeated excision procedures.
Preserved reproductive biology
A non-hormonal mechanism could potentially preserve ovulation, ovarian function and future reproductive choices.
A finite course of treatment
The ultimate goal is not lifelong medication. It is a defined intervention followed by durable remission.
Building NBetaX in public.
The NBetaX™ Research Journal records the evolution of the programme through dated scientific milestones. Science should leave a chronology. This is ours.
Endometriosis research, tracked as it publishes.
The literature around endometriosis, Wnt/β-catenin signalling and non-hormonal peptide therapeutics moves weekly. Recent entries below, refreshed from PubMed.
Recent developments in the field — refreshed 2026-10-16 by Panacea Bio Chem.
- Inflammation-fibrosis crosstalk in endometriosis: immune-stromal mechanisms linking lesion persistence to pain and infertility — PubMed, 2026
- Establishment of pathology-validated immortalized patient-derived ovarian endometriosis epithelial cell line — PubMed, 2026 Nov
- Diagnostic and mechanistic roles of miR-5584-5p in endometriosis via the FZD2-mediated Wnt/β-catenin EMT axis — PubMed, 2026 Aug 21
- Integrative mRNA and miRNA Profiling Identifies Shared and Subtype-Associated PI3K-AKT-mTOR Pathway Dysregulation and Candidate miRNA-Mediated Regulatory Interactions in Endometriosis-Associated Ovarian Cancers (EAOCs) — PubMed, 2026 Sep 4
Endometriosis is not a normal consequence of being born female. It is a biological disease.
Biological diseases have mechanisms. Mechanisms can be interrogated. Targets can be reached. And one day, the correct molecule may make the disease stop.
NBetaX™ is being built for that day.
Frequently asked
What are peptides?
Peptides are molecules made from two or more amino-acid residues joined by peptide bonds. In everyday biomedical use, the term usually refers to amino-acid chains smaller than proteins, although the exact size boundary is not absolute. Their biological activity depends on sequence, structure and chemical modifications rather than on the word “peptide” alone. — sources: IUPAC Gold Book — peptides, NCBI MeSH — Peptides, NCBI/NCI — peptide definition
How do peptides work in the body?
Many endogenous peptides act as signalling molecules. They bind to receptors, enzymes, membranes or other molecular partners and change cellular behaviour such as hormone release, metabolism, inflammation, growth or tissue signalling. Different peptides can have completely different targets, so “peptides” should never be treated as one biological effect. — sources: Nature Reviews Drug Discovery — Trends in peptide drug discovery, AAMC — 10 questions to ask your doctor about peptides, Tufts Medicine — Peptides explained
What is the difference between peptides and proteins?
Both peptides and proteins are built from amino acids. Peptides are generally shorter chains, while proteins are usually longer and more likely to adopt complex three-dimensional structures. The boundary is conventional rather than absolute, so sequence length alone does not fully determine whether a molecule is called a peptide or protein. — sources: NCBI MeSH — Peptides, Nature Reviews Drug Discovery — Trends in peptide drug discovery
Are peptides steroids?
No. Peptides are amino-acid chains linked by peptide bonds, whereas steroids are molecules built around a characteristic four-ring carbon framework. Some peptides and some steroids can influence overlapping physiological systems, which is why they are sometimes discussed together, but chemically they are very different classes of molecule. — sources: IUPAC Gold Book — peptides, Harvard Health — Peptides: benefits and safety concerns
Are peptides hormones?
Some peptides are hormones, but many are not. Insulin, glucagon, oxytocin and many other signalling molecules are peptide hormones, while other peptides function as neurotransmitters, growth factors, antimicrobial molecules, research probes or synthetic drug candidates. “Peptide” describes chemistry; “hormone” describes biological function. — sources: Nature Reviews Drug Discovery — Trends in peptide drug discovery, AAMC — 10 questions to ask your doctor about peptides
Are peptides the same as amino acids?
No. Amino acids are the individual molecular building blocks. Peptides are formed when two or more amino-acid residues are joined, typically through peptide bonds. A peptide’s properties emerge from the sequence, length, charge, conformation and modifications of its component residues. — sources: IUPAC Gold Book — peptides, NCBI MeSH — Peptides
What is a peptide bond?
A peptide bond is the amide linkage that connects the carbonyl carbon of one amino-acid residue to the nitrogen of another. Repeating peptide bonds create the backbone of peptide chains. The sequence and side chains attached to that backbone determine much of a peptide’s chemistry and biological recognition. — sources: IUPAC Gold Book — peptides
How many amino acids are in a peptide?
There is no universally rigid cutoff. Peptides contain at least two amino-acid residues; terms such as oligopeptide, polypeptide and protein overlap, and different fields use somewhat different length conventions. It is better to state the actual sequence length than rely on a single arbitrary peptide/protein boundary. — sources: NCBI MeSH — Peptides, IUPAC Gold Book — peptides
Are peptides natural or synthetic?
Both. Living organisms produce many peptides naturally, while laboratories can synthesize identical sequences, analogues or entirely designed sequences. Synthetic chemistry also allows non-natural amino acids, cyclization, lipidation and other modifications that can alter stability, potency or pharmacokinetics. — sources: Nature Reviews Drug Discovery — Trends in peptide drug discovery, PubMed — Fmoc Solid-Phase Peptide Synthesis
Why can two peptides have completely different effects?
A change in amino-acid sequence can alter charge, shape, receptor affinity, stability and cellular distribution. Even closely related peptides can therefore engage different targets or behave differently in solution and in vivo. Sequence and structure, not the generic label “peptide,” determine function. — sources: Nature Reviews Drug Discovery — Trends in peptide drug discovery, PubMed — Factors affecting peptide aggregation
Terminology
The NBetaX ladder: NBetaX (platform and therapeutic class) → N-BX (translational candidate family) → N-BX01 (lead candidate). The canonical name decomposes as Nuclear βeta-catenin eXclusion.
The target protein is indexed as beta-catenin, β-catenin, beta catenin, CTNNB1 (its gene) and catenin beta-1.
The pathway is indexed under Wnt: Wnt signalling (UK) / Wnt signaling (US), the canonical Wnt pathway, and the Wnt/β-catenin pathway, with its nuclear effectors TCF/LEF and TCF4, the co-activator BCL9, and the destruction-complex proteins Axin, APC and GSK3β. The nuclear step is described as nuclear translocation, nuclear localisation or nucleocytoplasmic distribution. PubMed indexes 69 records for endometriosis AND "Wnt signaling" (count verified 2026-09-08) — the literature of this programme lives under the Wnt vocabulary even though the programme's own name does not contain it.
The disease terms: endometriosis, endometriotic lesion, ectopic endometrium, eutopic endometrium, endometrioma and deep infiltrating endometriosis. Adenomyosis is an adjacent condition, not the same one.
The category terms: non-hormonal endometriosis treatment, disease-modifying endometriosis therapy, precision peptide, lesion regression, protein-protein interaction inhibitor, peptidomimetic, cell-penetrating peptide and stapled peptide.

























